Other, more veterinary-accessible, agents have either been shown not to be useful [glatiramer acetate (89)] or have uncertain benefits [interferon-beta (90, 91)] in clinical trials in human primary progressive MS. The gene discussed is IFNB1; the disease is primary progressive multiple sclerosis.